



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



DT-109

Item No. 41219

CAS Registry No.: 14857-82-0
Formal Name: glycylglycyl-L-leucine
Synonym: Gly-Gly-L-Leu
MF: C₁₀H₁₉N₃O₄
FW: 245.3
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

DT-109 is supplied as a solid. Aqueous solutions of DT-109 can be prepared by directly dissolving the solid in aqueous buffers. DT-109 is sparingly soluble (1-10 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

DT-109 is a tripeptide.¹ It reduces blood glucose levels in an oral glucose tolerance test (OGTT) in mice. DT-109 (1 mg/g per day) reduces non-fasting blood glucose levels, serum total cholesterol and LDL levels, and adipocyte hypertrophy in *Apo^{-/-}* mice. It reduces body fat mass, adipocyte hypertrophy, and hepatomegaly in a mouse model of diet-induced non-alcoholic steatohepatitis (NASH). DT-109 (500 mg/kg per day) also reverses hepatic steatosis and prevents the progression of fibrosis in a cynomolgus monkey model of NASH induced by a high-fat, high-fructose, and high-cholesterol diet.²

References

1. Rom, O., Liu, Y., Liu, Z., *et al.* Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. *Sci. Transl. Med.* **12**(572), eaaz2841 (2020).
2. Qu, P., Rom, O., Li, K., *et al.* DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates. *Cell Metab.* **35**(5), 742-757 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/06/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM